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Abstract 
Pomalidomide is a distinct oral IMiD
®
 immunomodulatory agent with direct antimyeloma, stromal-
support inhibitory, and immunomodulatory effects. The pivotal, multicenter, open-label, randomized 
phase 3 trial MM-003 compared pomalidomide + low-dose dexamethasone vs high-dose 
dexamethasone in 455 patients with refractory or relapsed and refractory multiple myeloma after 
failure of bortezomib and lenalidomide treatment. Initial results demonstrated significantly longer 
progression-free survival and overall survival with an acceptable tolerability profile for pomalidomide + 
low-dose dexamethasone vs high-dose dexamethasone. This secondary analysis describes patient 
outcomes by treatment history and depth of response. Pomalidomide + low-dose dexamethasone 
significantly prolonged progression-free survival and favored overall survival vs high-dose 
dexamethasone for all subgroups analyzed, regardless of prior treatments or refractory status. Both 
univariate and multivariate analyses showed that no variable relating to either the number (≤ or > 3) or 
type of prior treatment was a significant predictor of progression-free survival or overall survival. No 
cross-resistance with prior lenalidomide or thalidomide treatment was observed. Patients achieving a 
minimal response or better to pomalidomide + low-dose dexamethasone treatment experienced a 
survival benefit, which was even higher in those achieving at least a partial response (17.2 and 19.9 
months, respectively, as compared with 7.5 months for patients with less than minimal response). These 
data suggest that pomalidomide + low-dose dexamethasone should be considered a standard of care in 
patients with refractory or relapsed and refractory multiple myeloma regardless of prior treatment. 
ClinicalTrials.gov: NCT01311687; EudraCT: 2010-019820-30. 
 
  
Prior treatment and depth of response in MM-003  4 
 
 
Introduction 
The advent of agents such as lenalidomide (LEN), bortezomib (BORT), and thalidomide (THAL) 
throughout the treatment continuum of multiple myeloma (MM) has dramatically improved the survival 
of patients. According to the US Surveillance, Epidemiology, and End Results database, 5-year survival 
rates have increased from 29% during the period from 1990 to 1992 to 40% during the period from 2003 
to 2007.
1,2
 Recent trials incorporating BORT maintenance and LEN continuous therapy have extended 
first-line progression-free survival (PFS) to nearly 3 years in stem cell transplant–ineligible patients and 
beyond 3 years in transplant-eligible patients.
3-6
  
Despite these improvements in frontline patient management, most patients with MM will 
ultimately relapse and become refractory to previous therapies, leading to poor prognosis. A recent 
retrospective analysis of patients with advanced refractory or relapsed and refractory MM (RRMM), in 
whom BORT and immunomodulatory agents have failed, found that alkylating agents or 
cyclophosphamide together with corticosteroids or high-dose dexamethasone (HiDEX) were the most 
common classes of drugs used; corticosteroid monotherapy was also widely used but with limited 
efficacy.
7
 Only 24% of patients achieved partial response (PR) or better to any treatment after failure of 
BORT and an immunomodulatory agent, with a median overall survival (OS) of only 9 months for those 
who received further treatment and 3 months for those who did not; however, patients were more 
likely to have been treated with THAL than with LEN.
7
 Thus, new, effective therapies are needed for the 
management of patients who have exhausted treatment with BORT, LEN, and THAL.  
 In the treatment of RRMM, whether to switch agent classes (ie, from immunomodulatory agent 
to proteasome inhibitor or vice versa) or treat with another agent of the same class remains an open 
debate. Data on BORT retreatment, LEN therapy following THAL, and carfilzomib use after BORT have 
been mixed.
8-10
 In patients with newly diagnosed MM and early RRMM, better depth of response has 
been associated with improvements in outcome measures, such as survival and duration of response 
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(DOR).
11-15
 In most of these patients, a deep response (≥ very good partial response [VGPR]) is the 
treatment goal. However, in patients with RRMM, minimal response (MR) may also be a clinically 
relevant outcome of treatment. 
 The distinct oral IMiD
®
 immunomodulatory agent pomalidomide (POM) has been shown to 
exhibit direct antimyeloma, stromal-support inhibitory, and immunomodulatory effects.
16,17
 Phase 2 
clinical trial results have demonstrated the efficacy and safety of POM with low-dose dexamethasone 
(LoDEX) in the treatment of patients with RRMM.
18-21
 POM + LoDEX was compared with HiDEX in 
patients with RRMM after failure of BORT and LEN in the international, multicenter, open-label, 
randomized phase 3 trial MM-003.
22
 POM + LoDEX treatment was found to significantly improve PFS and 
OS. This benefit was also observed in patients refractory to LEN as their last prior treatment. Consistent 
with the established tolerability profile of POM + LoDEX,
18-21
 the most common grade 3/4 adverse 
events observed for POM + LoDEX were hematologic (neutropenia, anemia, and thrombocytopenia).
8-21
 
The current publication reports efficacy from the MM-003 trial by depth of response, number of prior 
therapies, and types of prior therapies in the MM-003 trial. 
 
Methods 
Study design and patients 
MM-003 was an open-label, randomized, phase 3 registration trial conducted in 93 centers in 
Europe, Russia, Australia, Canada, and the United States. All patients provided written informed 
consent. The study was approved by institutional review boards or independent ethics committees at all 
participating centers and was conducted in accordance with the Declaration of Helsinki and the 
International Conference on Harmonization Guidelines on Good Clinical Practice. This trial is registered 
with ClinicalTrials.gov (NCT01311687) and EudraCT (2010-019820-30). All authors and the sponsor were 
involved in the data gathering and analysis, review, interpretation, and writing of the report. 
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Full study results have previously been reported.
22
 Briefly, patients were aged ≥ 18 years and 
must have had RRMM treated with ≥ 2 prior antimyeloma regimens, been refractory to their last prior 
treatment, failed prior treatment with BORT and LEN (following ≥ 2 previous consecutive cycles of each, 
alone or in combination), and received adequate prior alkylator therapy. Failure of BORT or LEN therapy 
was defined as progressive disease during or within 60 days of completing treatment, progressive 
disease ≤ 6 months after achieving PR or better, or intolerance without achieving MR or better (BORT 
only).  
Four hundred fifty-five patients were randomized in a 2:1 ratio to receive 28-day cycles of POM 
(4 mg/day orally on days 1-21) + LoDEX (40 mg/day orally on days 1, 8, 15, and 22) or HiDEX  
(40 mg/day orally on days 1-4, 9-12, and 17-20). For both arms, DEX was administered at a dose of 20 
mg/day for patients aged ≥ 75 years. Treatment was continued until progression or unacceptable 
toxicity. Thromboprophylaxis consisting of physician’s choice of low-dose aspirin or low-molecular-
weight heparin (or equivalent) was required for all patients who received POM and those at high risk of 
developing thrombosis. 
 
Assessments and statistical analysis 
The primary endpoint was PFS, with treatment groups compared using a log-rank test. 
Secondary endpoints included OS, overall response rate (ORR; the proportion of patients achieving a PR 
or better), time to progression (TTP), DOR, safety, and quality of life. The PFS and ORR presented in this 
report were based on investigator assessment using International Myeloma Working Group criteria
23
 or 
European Group for Blood and Marrow Transplant criteria
24
 (for MR only). Reduction in levels of M-
protein was also assessed.  
 The Kaplan-Meier product-limit method was used to estimate PFS, OS, and DOR, which were 
then compared between treatment groups using log-rank tests stratified by age, disease population, and 
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number of prior antimyeloma therapies. ORR was compared between treatment arms using the Fisher 
exact test. Subgroup analyses for PFS and OS were carried out using unstratified log-rank tests and 
presented in forest plots. Multivariate analyses were also performed using a Cox model to assess the 
effect of prior therapies on PFS and OS. 
 
Results 
Patient characteristics 
The reported analysis used the most recent data available for MM-003 (cutoff September 1, 
2013; median follow-up, 15.4 months). Patient disposition is shown in Figure 1. Baseline characteristics 
were well balanced between treatment arms, as previously described.
22
 Per protocol, this heavily 
pretreated patient population (median, 5 lines of prior therapy in both arms) had received prior LEN and 
BORT (Table 1). Nearly all patients were refractory to LEN (POM + LoDEX arm, 95%; HiDEX arm, 92%), 
and most were refractory to both LEN and BORT (POM + LoDEX, 75%; HiDEX, 74%).  
 
Survival and response (intent-to-treat population) 
In the intent-to-treat population, with extended follow-up, median PFS was significantly longer 
with POM + LoDEX vs HiDEX (4.0 vs 1.9 months; hazard ratio [HR], 0.50; P < .001). Median OS was 
significantly longer for POM + LoDEX vs HiDEX (13.1 vs 8.1 months; HR, 0.72; P = .009). This OS 
advantage was observed despite 85 patients (56%) on the HiDEX arm receiving subsequent POM. A 
significantly higher ORR (PR or better) was achieved in patients treated with POM + LoDEX vs HiDEX 
(32% vs 11%; P < .001). Forty percent of patients receiving POM + LoDEX and 15% of patients receiving 
HiDEX achieved an MR or better. The median DOR (for patients with a PR or better) was also significantly 
longer with POM + LoDEX than with HiDEX (7.5 vs 5.1 months; P = .031). Eighty-two percent of patients 
receiving POM + LoDEX and 61% of patients receiving HiDEX achieved disease control (stable disease or 
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better). In these patients, POM + LoDEX demonstrated a statistically significant improvement in PFS vs 
HiDEX (4.9 vs 2.8 months; P < .001). Even when patients whose best response was stable disease were 
analyzed alone, POM + LoDEX still significantly improved PFS vs HiDEX (3.5 vs 2.5 months; P = .034). A 
number of patients who did not respond within the first 2 to 3 treatment cycles subsequently did 
achieve a response (or PR). In POM + LoDEX– vs HiDEX-treated patients, 58 vs 5, 16 vs 4, and 20 vs 5 
patients responded within 9 weeks, between 9 and 13 weeks, and after 13 weeks, respectively.    
 
Survival and response based on prior treatment 
PFS significantly favored POM + LoDEX vs HiDEX, regardless of number or type of prior therapies, 
and a similar trend was observed for OS (Figure 2). PFS and OS benefits were maintained in patients who 
had LEN-refractory disease (PFS: HR, 0.51 [95% CI, 0.41-0.64]; OS: HR, 0.70 [95% CI, 0.55-0.90]), even in 
patients refractory to LEN as their last prior treatment (PFS: HR, 0.41 [95% CI, 0.28-0.62]; OS: HR, 0.56 
[95% CI, 0.36-0.88]).  
Response rates to POM + LoDEX were similar regardless of number and type of prior therapies 
(Figure 3). Patients who were refractory to LEN (n = 286), BORT (n = 238), or both (n = 225) had similar 
ORRs (30% vs 31% vs 29%). Response was not significantly different among patients who were refractory 
to LEN (n = 85) or BORT (n = 134) as last prior therapy (33% vs 34%). ORR was similar between patients 
with (n = 173) and without (n = 129) prior treatment with THAL (31% vs 34%) and in the 214 patients 
with prior stem cell transplant (31%). 
TTP for patients treated with POM + LoDEX was significantly longer than that with their last line 
of therapy, although the difference is unlikely to be clinically meaningful (median, 4.7 vs 4.4 months; HR, 
0.79; P = .008). In contrast, patients treated with HiDEX progressed significantly more quickly than with 
their last prior line of therapy (median, 2.1 vs 4.3 months; HR, 1.76; P < .001; Figure 4). 
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Multivariate analysis found that no variable relating to the number or type of prior treatments 
was a significant predictor of PFS or OS (Table 2). Factors analyzed included LEN or BORT as last prior 
therapy and LEN-, BORT -, or double-refractory status. 
 
Survival based on depth of response 
PFS and OS were assessed in patients according to the level of reduction in M-protein levels on 
POM + LoDEX treatment. Median PFS in POM + LoDEX–treated patients with reductions of < 25%, ≥ 25%, 
and ≥ 50% was 2.3, 7.4, and 8.4 months, respectively. Median OS in POM + LoDEX–treated patients with 
reductions of < 25%, ≥ 25%, and ≥ 50% was 7.5, 17.2, and 19.9 months, respectively (Figure 5). The trend 
associating a greater level of M-protein response with longer PFS and OS was also seen in very elderly 
patients (> 75 years) and in patients with and without high-risk cytogenetic factors (Table 3). 
 
 
Discussion 
Initial MM-003 results, with a median follow-up of 10 months, demonstrated significantly longer 
PFS and OS for patients who received POM + LoDEX than for those who received HiDEX.
22
 Longer follow-
up (median, 15.4 months) has confirmed significant PFS (4.0 vs 1.9 months; P < .001) and OS (13.1 vs 8.1 
months; P = .009) benefits for POM + LoDEX vs HiDEX.
22
 Our subanalysis has shown that these benefits 
are generally maintained regardless of the number or type of prior therapies, including in patients with ≤ 
3 and > 3 prior therapies, with or without prior THAL exposure, with LEN or BORT as last prior therapy, 
and refractory to LEN, BORT, or both. Multivariate analysis also found no effect of prior treatment on 
PFS or OS. This analysis demonstrated that approximately one-third of heavily pretreated patients (> 3 
prior lines of therapy) will respond to POM + LoDEX. These findings are consistent with results from the 
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phase 2 MM-002 study comparing POM + LoDEX with single-agent POM, in which PFS and OS in POM + 
LoDEX–treated patients were similar regardless of prior therapies or last prior therapy.
18
  
The current analysis showed that benefits of POM + LoDEX treatment remain consistent 
regardless of prior treatment, even after repeated agents of the same class. This is a relevant finding in 
that it fails to support the usual assumption of cross-resistance between drugs of the same class; in fact, 
at least partial resistance has been suggested when carfilzomib is given immediately following BORT.
10
 
Specifically, the ORR for patients treated with POM + LoDEX after LEN as last prior treatment was 33%, 
similar to the 32% for the overall POM + LoDEX population, indicating that there is no cross-resistance 
between POM and prior treatment with an immunomodulatory agent. This is consistent with in vitro 
data demonstrating antimyeloma effects of POM on LEN-resistant MM cell lines.
25,26
 These results 
support the use of immunomodulatory agents in succession and show that prior LEN treatment should 
not preclude the use of POM.  
Depth of response to POM + LoDEX was associated with a survival benefit for patients achieving 
a ≥ 25% reduction in M-protein levels. This pattern was consistent in very elderly patients (> 75 years) 
and those with high-risk cytogenetics, demonstrating that a ≥ 25% reduction in M-protein levels predicts 
PFS and OS benefits even in these populations with a poor prognosis. The benefit is even more evident 
for patients achieving a reduction of ≥ 50% in M-protein levels. Depth of response in other studies has 
also been found to be associated with longer PFS and/or OS in patients previously exposed to novel 
agents; these include trials of single-agent carfilzomib,
10
 POM in combination with cyclophosphamide 
and prednisone,
27
 and combination therapy with panobinostat, BORT, and DEX.
28
  
 These subanalyses of MM-003 data further support that POM + LoDEX can provide consistent 
clinical benefits and tolerability to patients with RRMM regardless of prior therapy. This regimen should 
be considered a standard of care in this patient population. 
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Table 1. Prior Therapies 
POM + LoDEX 
(n = 302) 
HiDEX 
(n = 153) 
Median number (range) 5 (2-14) 5 (2-17) 
Prior DEX, % 98 99 
Prior THAL, % 57 61 
Prior SCT, % 71 69 
Prior LEN, % 100 100 
Prior BORT, % 100 100 
Prior alkylator, % 99 98 
LEN refractory, % 95 92 
BORT refractory, % 79 79 
LEN and BORT refractory, % 75 74 
 
BORT, bortezomib; DEX, dexamethasone; HiDEX, high-dose dexamethasone; LEN, lenalidomide; LoDEX, 
low-dose dexamethasone; POM, pomalidomide; SCT, stem cell transplant; THAL, thalidomide. 
  
Prior treatment and depth of response in MM-003  18 
 
 
Table 2. Multivariate Analysis for PFS and OS  
PFS OS 
Parameter 
Hazard Ratio   
(95% CI) 
P Value 
Hazard Ratio  
(95% CI) 
P Value 
Treatment arm 
 (POM + LoDEX vs HiDEX) 
0.49 (0.39-0.60) < .001 0.70 (0.55-0.90) .005 
Age (≤ 65 vs > 65 years) 0.97 (0.79-1.19) .79 0.87 (0.68-1.10) .24 
No. of prior Tx (≤ 3 vs > 3) 0.91 (0.70-1.17) .45 1.18 (0.86-1.60) .31 
Prior THAL 0.89 (0.71-1.11) .29 1.05 (0.81-1.37) .71 
LEN refractory 1.43 (0.65-3.11) .37 2.00 (0.62-6.45) .25 
BORT refractory 1.51 (0.61-3.73) .38 2.15 (0.60-7.75) .24 
LEN and BORT refractory 0.74 (0.29-1.88) .53 0.63 (0.17-2.34) .49 
Refractory to last LEN Tx 1.02 (0.80-1.30) .87 0.93 (0.70-1.25) .64 
Refractory to last BORT Tx 0.91 (0.72-1.14) .41 0.79 (0.60-1.04) .09 
 
BORT, bortezomib; HiDEX, high-dose dexamethasone; LEN, lenalidomide; LoDEX, low-dose 
dexamethasone; OS, overall survival; PFS, progression-free survival; POM, pomalidomide; THAL, 
thalidomide; Tx, treatment. 
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Table 3. Survival by Depth of Response in Very Elderly (> 75 Years) and Cytogenetic Risk Groups 
POM + LoDEX 
Patients n 
Median 
PFS, mo 
Median 
OS, mo 
Age > 75 years    
M-protein level reduction ≥ 50% 10 11.5  NE 
M-protein level reduction ≥ 25% 13 11.5 22.9 
M-protein level reduction < 25% 11 1.6 9.8 
High-risk cytogenetics
a
    
M-protein level reduction ≥ 50% 23 5.5 16.4 
M-protein level reduction ≥ 25% 35 5.6 15.5 
M-protein level reduction < 25% 29 2.8 6.0 
Standard-risk cytogenetics
b
    
M-protein level reduction ≥ 50% 57 8.4 22.4 
M-protein level reduction ≥ 25% 85 7.4 17.3 
M-protein level reduction < 25% 46 2.4 10.5 
LoDEX, low-dose dexamethasone; NE, not evaluable; OS, overall survival; PFS, progression-free survival; 
POM, pomalidomide. 
a 
High-risk cytogenetics are defined as the presence of del(17p) and/or t(4;14). 
b 
Standard-risk cytogenetics are defined as the absence of both del(17p) and t(4;14).  
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Figure legends 
 
Figure 1. Disposition of MM-003 trial participants as of September 1, 2013. AE, adverse event; HiDEX, 
high-dose dexamethasone; LoDEX, low-dose dexamethasone; PD, progressive disease; POM, 
pomalidomide; Tx, treatment. 
 
Figure 2. Forest plot of progression-free survival (A) and overall survival (B) based on prior treatment.  
a 
Number of events/number of patients. BORT, bortezomib; HiDEX, high-dose dexamethasone; HR, 
hazard ratio; ITT, intent-to-treat; LEN, lenalidomide; LoDEX, low-dose dexamethasone; POM, 
pomalidomide; ref, refractory; SCT, stem cell transplant; THAL, thalidomide; Tx, treatment.  
 
Figure 3. Response (by International Myeloma Working Group criteria) to POM + LoDEX treatment by 
prior therapy. Percentages may not sum due to rounding. BORT, bortezomib; LEN, lenalidomide; LoDEX, 
low-dose dexamethasone; POM, pomalidomide; PR, partial response; SCT, stem cell transplant; THAL, 
thalidomide; Tx, treatment; VGPR, very good partial response.  
  
Figure 4. TTP on study compared with last prior therapy. HiDEX, high-dose dexamethasone; HR, hazard 
ratio; LoDEX, low-dose dexamethasone; POM, pomalidomide; TTP, time to progression; Tx, treatment. 
  
Figure 5. PFS (A) and OS (B) by depth of response measured by degree of M-protein level reduction for 
patients assigned to POM + LoDEX. LoDEX, low-dose dexamethasone; OS, overall survival; PFS, 
progression-free survival; POM, pomalidomide.        





